View Schedule

34th Annual Meeting & Pre-Conference Programs Schedule

Wednesday, Nov. 6, 2019
World Immunotherapy Council’s 3rd Young Investigator Symposium
Time:

8 a.m. - 1 p.m.

Novel Multi-Targeted Therapeutic Platforms
Time:

2 - 6:30 p.m.

Thursday, Nov. 7, 2019
Primer on Tumor Immunology and Cancer Immunotherapy™
8 a.m.

Introduction
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

Primer Session 1: Tumor Immunity I

Time:

8:05 9:55 a.m.

8:05 a.m.

Adaptive Immunity to Tumors and Cytokines: Laying the Foundation for Immunotherapy
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine

8:35 a.m.

Macrophages, Dendritic and Myeloid Cells

9:05 a.m.

Harnessing Natural Killer Cells and Innate Lymphoid Cells to Potentiate Antitumor Immunity
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

9:35 a.m.

Tumor Immunity I Panel Discussion
Moderator: Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Panelists:
Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Amir Horowitz, PhD – Icahn School of Medicine at Mount Sinai

9:55 a.m.

Break

Primer Session 2: Tumor Immunity II

Time:

10:10 a.m. 12 p.m.

10:10 a.m.

Immunometabolism and the Microbiome
Greg Delgoffe, PhD – University of Pittsburgh

10:40 a.m.

Cancer Vaccines : From Ex Vivo Production to In Vivo Vaccination
Tanja de Gruijl, PhD – VU University Medical Center

11:10 a.m.

Monoclonal Antibodies and Their Derivatives

11:40 a.m.

Tumor Immunity II Panel Discussion
Moderator: Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Panelists:
Tanja de Gruijl, PhD – VU University Medical Center
Greg Delgoffe, PhD – University of Pittsburgh

12 p.m.

Lunch

Primer Session 3: Analysis of Resistance and Response

Time:

1 2:55 p.m.

1 p.m.

Introduction
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center

1:05 p.m.

Mechanisms of Extrinsic Resistance : A Miserable Microenvironment
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center

1:35 p.m.

Mechanisms of Resistance: Checkpoint Receptors
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

2:05 p.m.

Biomarkers of Response to Immunotherapy
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

2:35 p.m.

Analysis of Resistance and Response Panel Discussion
Moderator: Jonathan Powell, MD, PhD – Johns Hopkins University School of Medicine
Panelists:
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Sacha Gnjatic, PhD – Icahn School of Medicine at Mount Sinai

2:55 p.m.

Break

Primer Session 4: Current IO Immunotherapy

Time:

3:10 4:55 p.m.

3:10 p.m.

Adoptive T Cell Therapy
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center

3:40 p.m.

Combination Therapies
Leisha Emens, MD, PhD – University of Pittsburgh

4:10 p.m.

Adverse Events
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine

4:40 p.m.

Current IO Immunotherapy Panel Discussion
Moderator: Michael A. Curran, PhD – University of Texas MD Anderson Cancer Center
Panelists:
Leisha Emens, MD, PhD – University of Pittsburgh
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
Jarushka Naidoo, M.B.B.Ch – Johns Hopkins Medicine

4:55 p.m.

Closing

5 p.m.

Adjourn

Workshop on Intratumoral Immunomodulation
8 a.m. Introduction
Workshop Session 1: Introduction to Intratumoral Immunomodulation
Time:

8:05 9:05 a.m.

8:05 a.m.

Background

8:25 a.m.

Cold vs. Hot Tumors

8:45 a.m.

Target Cells
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

Workshop Session 2: Modes of Delivery
Time:

9:05 10:25 a.m.

9:05 a.m.

Introduction to Intratumoral Therapy
Aurélien Marabelle, MD, PhD – Gustave Roussy

9:20 a.m.

Modes of Intratumoral Injections: Complexities and Approaches

9:45 a.m.

Role of Radiation in STING Activation
Sandra Demaria, MD – Weill Cornell Medicine

10:05 a.m.

SBRT and Immune Activation
Silvia Formenti, MD – New York-Presbyterian/Weill Cornell Medical Center

10:25 a.m.

Break

Workshop Session 3: Intratumoral Synthetic Modulators
Time

10:40 a.m. 12 p.m.

10:40 a.m.

TLR3
Joshua Brody, MD – Icahn School of Medicine at Mount Sinai

11 a.m.

TLR9
Adi Diab, MD – University of Texas MD Anderson Cancer Center

11:20 a.m

TLR7/8
Willem W. Overwijk, PhD – Nektar Therapeutics

11:40 a.m.

STING Pathways
Thomas W. Dubensky, PhD – Tempest Therapeutics

12 p.m.

Lunch

Workshop Session 4: Intratumoral Oncolytic Modulators
Time:

1 2 p.m.

1 p.m.

T-VEC
Howard L. Kaufman, MD, FACS – Replimune Group Inc.

1:20 p.m.

Newcastle Disease Virus Therapy in Cancer

1:40 p.m.

Oncolytic Viruses
John Bell, PhD – University of Ottawa

Workshop Session 5: Systemic Combinations

Time:

2 4:55 p.m.

2 p.m.

Intratumoral Checkpoint Blockade Inhibition
Craig L. Slingluff, MD – University of Virginia

2:20 p.m.

Anti-Tumor Vaccines Platforms
Esteban Celis, MD, PhD – Augusta University

2:40 p.m.

Break

3 p.m.

CD40: A Target for Systemic Immune Modulation

3:20 p.m.

Clinical Assessment of Intratumoral Immunomodulation
Jianda Yuan, MD, PhD – Merck Research Laboratories

3:40 p.m.

Regulatory Implications for Drug Development

4 p.m.

Systemic Combinations Panel Discussion
Moderators: Adi Diab, MD – University of Texas MD Anderson Cancer Center
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

Panelists:
Craig L. Slingluff, MD – University of Virginia
Jianda Yuan, MD, PhD – Merck Research Laboratories

4:55 p.m.

Closing

5 p.m.

Adjourn

Annual Meeting Session 100: Hematologic Malignancies
Organized in collaboration with the American Society of Hematology (ASH).
Time: 1 5 p.m.
Co-Chairs:

Katayoun Rezvani, MD, PhD The University of Texas MD Cancer Center
John M. Timmerman, MD University of California, Los Angeles

Poster Symposium
Time: 5:30 7:30 p.m.

Grant Writing Workshop
Time:

6 - 7:55 p.m.

6:05 p.m.

Overview of Grant Opportunities
Pawel Kalinski, MD, PhD – Roswell Park Comprehensive Cancer Institute

6:15 p.m.

Principles of Grant Writing
Thomas Gajewski, MD, PhD – University of Chicago

6:35 p.m.

Panel Discussion

6:45 p.m.

A Look Inside a Study Section

6:50 p.m.

Mock Study Session

7:25 p.m.

What Happens After Reviews are Conducted/How to Revise Your Grant

7:40 p.m.

Panel Discussion

7:55 p.m.

Closing Remarks


Friday, Nov. 8, 2019
Session 200: Update Session

Time:

8:05 8:35 a.m.

Session 201: Richard V. Smalley, MD Memorial Lectureship

Time:

8:35 – 9:25 a.m.

Chair:

Mario Sznol, MD – Yale School of Medicine

8:35 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

8:40 a.m. Traveling the Cancer Vaccine Road and Reaching My Destination
Olivera J. Finn, PhD – University of Pittsburgh School of Medicine
9:20 a.m.

Question & Answers
Olivera J. Finn, PhD – University of Pittsburgh School of Medicine

Session 202: Autoimmunity, Toxicity, and Cancer Immunotherapy

Time:

9:25 a.m. 12 p.m.

Co-Chairs:

Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center
Virginia Pascual, MD – Weill Cornell Medicine

9:25 a.m.

Introduction

9:30 a.m.

Clinical irAE
Jarushka Naidoo, MD – Johns Hopkins Sidney Kimmel Cancer Center

9:50 a.m.

Basic Mechanisms in Autoimmunity/ Novel, New Data on T cells
Virginia Pascual, MD – Weill Cornell Medicine

10:10 a.m.

Break

10:25 a.m.

Autoantibodies

10:45 a.m.

Colitis
Michael L. Dougan, MD, PhD – Massachusetts General Hospital

11:05 a.m.

Abstract Presentation

11:20 a.m.

Abstract Presentation

11:35 a.m.

Panel Discussion

Session 203: Late-Breaking Abstract Session
Time: 12 12:30 p.m.
Chair: Ana Carrizosa Anderson, PhD – Harvard Medical School
12 p.m. Abstract Presentation
12:15 p.m. Abstract Presentation
Lunch, Exhibits and Poster Viewing
Time: 12:30 2 p.m.
Concurrent Rapid Oral Abstract Presentations - Basic Research
Time: 12:45 1:45 p.m.
Concurrent Rapid Oral Abstract Presentations - Clinical
Time: 12:45 1:45 p.m.
Session 204: Immune Checkpoints: Newer Targets and Update on Combinations
Time: 2 4:20 p.m.
Co-Chairs: Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center
2 p.m. Introduction
2:05 p.m. Targeting CD38 to optimize PD-1/PD-L1 and CTLA-4 Blockade Immunotherapy
2:25 p.m.

Combinations: IL-2
Adi Diab, MD – University of Texas MD Anderson Cancer Center

2:45 p.m. The Emerging Role of TLR Agonists in Cancer Immunotherapy
3:05 p.m.

Novel Targets: TIM-3
Hassane M. Zarour, MD – UPMC Hillman Cancer Center

3:25 p.m. Immune Contexture and Immune Escape at Pre-Cancer Lesion Stages
Jérôme Galon, PhD – INSERM, Sorbonne Universites Paris
3:45 p.m. Abstract Presentation
4 p.m. Panel Discussion
Moderators: Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center
Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center

Panelists:
Hassane M. Zarour, MD – UPMC Hillman Cancer Center
4:15 p.m. Closing
Concurrent Session 205: Biology of T cells
Time: 4:50 6:15 p.m.
Co-Chairs: Rafi Ahmed, PhD – Emory University
Ana Carrizosa Anderson, PhD – Harvard Medical School
4:50 p.m. T cell Responses in Tumor, Chronic Antigen Stimulation, T cell Exhaustion
Dietmar Zehn, PhD, MD – Technical University of Munich
5:15 p.m. Single Cell Profiling of Anti-Tumor T cell Response
Enrico Lugli, PhD – Instituto Clinico Humanitas IRCCS
5:40 p.m. Biology of T cells
6:05 p.m. Abstract Presentation
Concurrent Session 206: High Impact Clinical Trials
Time: 4:50 6:15 p.m.
Co-Chairs: Jeffrey Weber, MD, PhD – NYU Langone Medical Center
4:50 p.m. Introduction
4:55 p.m. Abstract Presentation
5:10 p.m. Abstract Presentation
5:25 p.m. Abstract Presentation
5:40 p.m. Abstract Presentation
5:55 p.m. Abstract Presentation
6:10 p.m. Closing
Concurrent Session 207: Harnessing Antigen-Presenting cells to Boost Anti-Tumor Immunity
Time: 4:50 6:15 p.m.
Co-Chairs: Matthew Krummel, PhD – University of California, San Francisco
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

4:50 p.m.

DC Subsets,T cell Interactions, Tumor-Resident, and Murine Studies
Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

5:10 p.m.

Phagocytic cells, Migratory cells, and Human Studies
Matthew Krummel, PhD – University of California, San Francisco

5:30 p.m. Basic Biology of Phagocytic cells
Julie Blander, PhD – Weill Cornell Medicine
5:50 p.m. Abstract Presentation
6 p.m. Abstract Presentation
6:10 p.m. Abstract Question and Answer
Concurrent Session 208: Tumor Cell Atlas Efforts Big Data
Time: 4:50 6:15 p.m.
Chair: Orit Rozenblatt-Rosen, PhD – Broad Institute
4:50 p.m. Progression
5:05 p.m. Interactions
5:20 p.m. Tutorial
5:35 p.m. Computational
5:50 p.m. Abstract Presentation
6:05 p.m. Question & Answers
Concurrent Session 209: Virus Driven Cancers
Time:

4:50 6:15 p.m.

Co-Chairs:

Robert Ferris, MD, PhD – UPMC Hillman Cancer Center
Weijing Sun, MD, FACP – University of Kansas Medical Center

4:50 p.m.

HPV and Head and Neck Cancers
Robert Ferris, MD, PhD – UPMC Hillman Cancer Center

5:05 p.m.

EBV and Cancers

5:20 p.m.

Liver Cancer

5:35 p.m.

Merkel Cell Carcinoma
Suzanne L. Topalian, MD – Johns Hopkins University School of Medicine

5:50 p.m.

Abstract Presentation

6 p.m.

Abstract Presentation

6:10 p.m. Question & Answers


Saturday, Nov. 9, 2019

Organizer Welcome

7:50 a.m.

Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Session 300: Update Session

Time:

7:55 8:25 a.m.

Session 301: Update Session

Time:

8:25 – 8:55 a.m.

Session 302: Keynote Address

Time:

8:55 9:45 a.m.

Chair:

Mario Sznol, MD – Yale School of Medicine

8:55 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

9 a.m.

Using Advanced Multiplex Optical Imaging Methods to Study the Tumor Micro-environment and Response to Cancer Immunotherapy
Ronald N. Germain, MD, PhD – NIAID, NIH

9:40 a.m.

Question & Answers
Ronald N. Germain, MD, PhD – NIAID, NIH

Session 303: Imaging Technologies

Time: 9:45 11:50 a.m.

Co-Chairs:

Carlo Bifulco, MD – Providence Portland Medical Center
Michael Dustin, PhD – The Kennedy Institute of Rheumatology

9:45 a.m.

Introduction

9:50 a.m.

Super-Resolution/ Fast Microscopy

10:05 a.m.

Cryoelectron Microscopy

10:20 a.m.

Multiplexed Imaging of Tissues- MIBI or CODEX
Michael Angelo, MD, PhD – Stanford Medicine

10:35 a.m.

Break

10:50 a.m.

DNA Microscopy

11:05 a.m.

Whole Body Imaging Technology
Anna M. Wu, PhD – University of California, Los Angeles

11:20 a.m.

Intravital Imaging

11:35 a.m.

Abstract Presentation

Session 304: Late-Breaking Abstract Session

Time:

11:50 a.m. 12:20 p.m.

Chair:

Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center

11:50 a.m.

Abstract Presentation

12:05 p.m.

Abstract Presentation

Session 305: Sparkathon Update
Time:

12:20 12:35 p.m.

12:20 p.m.

Sparkathon Update
Jennifer L. Guerriero, PhD – Dana-Farber Cancer Institute

Lunch, Exhibits, and Poster Viewing
Time:

12:50 – 1:50 p.m.

Concurrent Rapid Oral Abstract Presentations - Basic
Time:

12:50 – 1:50 p.m.

Concurrent Rapid Oral Abstract Presentations - Clinical
Time:

12:50 – 1:50 p.m.

Session 306: Presidential Session
Time:

2:05 3:30 p.m.

Chair:

Mario Sznol, MD – Yale School of Medicine

2:05 a.m.

Introduction
Mario Sznol, MD – Yale School of Medicine

2:10 p.m.

Abstract Presentation

2:25 p.m.

Abstract Presentation

2:40 p.m. Expert Discussant
2:50 p.m. Abstract Presentation
3:05 p.m. Abstract Presentation
3:20 p.m. Expert Discussant
Concurrent Session 307: Machine Learning Approaches and Applications
Time:

3:45 5 p.m.

Co-Chairs:

Douglas Lauffenburger, PhD – Massachusetts Institute of Technology
Kurt A. Schalper, MD, PhD – Yale School of Medicine

3:45 p.m.

Clinical Biomarkers
Kurt A. Schalper, MD, PhD – Yale School of Medicine

4 p.m.

Deciphering the TME
Kathryn Miller-Jensen, PhD – Yale University

4:15 p.m.

Deep Learning Algorithms
Douglas Lauffenburger, PhD – Massachusetts Institute of Technology

4:30 p.m. Enhancing Predictors of Neoantigens and TCRs
Marta Łuksza, PhD – Mount Sinai
4:45 p.m. Abstract Presentation
Concurrent Session 308: Clinical Management
Time:

3:45 5 p.m.

Co-Chairs:

Marianne Davies, DNP, AOCNP – Yale School of Nursing
Elad Sharon, MD, MPH – National Cancer Institute

3:45 p.m. Response Criteria/ Patient Selection
Victoria L. Chiou, MD – Food & Drug Administration
4:05 p.m. Management of Patients in a Clinical Setting
Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4:25 p.m.

Combining Toxicity Management Strategies from a Program Perspective

4:45 p.m

Abstract Presentation

Concurrent Session 309: Single Agent Phase 1 Clinical Trials
Time: 3:45 5 p.m.
Co Chairs: Naiyer Rizvi, MD – Columbia University Medical Center
3:45 p.m. Abstract Presentation
4 p.m. Abstract Presentation
4:15 p.m. Abstract Presentation
4:30 p.m. Abstract Presentation
4:45 p.m. Abstract Presentation
Break
Time:

5 5:15 p.m.

Concurrent Session 310: Combination Phase 1-2 Clinical Trials

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Adil Daud, MBBS, MD – University of California, San Francisco

5:15 p.m.

Abstract Presentation

5:30 p.m.

Abstract Presentation

5:45 p.m.

Abstract Presentation

6 p.m.

Abstract Presentation

6:15 p.m.

Abstract Presentation

Concurrent Session 311: A Tale of Two Brain Tumors: Primary versus Metastatic CNS Tumors

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Hideho Okada, MD, PhD – University of California, San Francisco
David Reardon, MD – Dana-Farber Cancer Institute

5:15 p.m.

Immunobiology of Primary CNS Tumors
Robert Prins, PhD – University of California, Los Angeles

5:35 p.m.

Immunobilogy of CNS Metastatic Tumors
Harriet M. Kluger, MD – Yale School of Medicine

5:55 p.m.

Difference Between the Application of Adoptive Cellular Therapy for Primary versus Metastatic Tumors
Richard M. Sherry, MD – National Institutes of Health

6:15 p.m.

Abstract Presentation

Concurrent Session 312: NK Cells: From Basic Science to Clinical Application

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai
David Raulet, PhD – University of California, Berkeley

5:15 p.m.

Basic Science

Eric Vivier, DVM, PhD – Aix Marseille University, Publique de Hôptiaux de Marseille, Innate-Pharma

5:35 p.m.

NK Cells and Bladder Cancer
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

5:55 p.m.

NK Cell Biology and Application to Therapy Options
David Raulet, PhD – University of California, Berkeley

6:15 p.m.

Abstract Presentation

Concurrent Session 313: Immunotherapy Advances in Skin Cancer

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Shailender Bhatia, MD – University of Washington
Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori-Fondazione 'G. Pascale'

5:15 p.m.

Immunotherapy Advances in Non-Melanoma Skin Cancer
Shailender Bhatia, MD – University of Washington

5:35 p.m.

Advances in Melanoma Adjuvant Therapy: Implications for Clinical Practice and Future Research
Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center

5:55 p.m.

Immunotherapy Advances in Melanoma
Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori-Fondazione 'G. Pascale'

6:15 p.m.

Abstract Presentation

Concurrent Session 314: Tumor and Stromal Cell Biology

Time:

5:15 – 6:30 p.m.

Co-Chairs:

Kwok-Kin Wong, MD, PhD – New York Langone Health
Neta Erez, PhD – Tel Aviv University

5:15 p.m.

Pancreatic Cancer

5:35 p.m.

Tumor Progression
Ashani Weeraratna, PhD – The Wistar Institute

5:55 p.m.

Tumor Microenvironment

6:15 p.m.

Abstract Presentation

Award Ceremony

Time:

6:30 – 7 p.m.

Poster Reception

Time:

7 – 8:30 p.m.

The Checkpoints Band Party

Time:

8:30 – 11:30 p.m.

Sunday, Nov. 10, 2019

Organizer Welcome
8 a.m.

Marianne Davies, DNP, AOCNP – Yale School of Nursing

Session 400: Innovations in Cellular Therapy for Therapeutically Targeting Advanced Malignancies

Time:

8:05 10:15 a.m.

Co-Chairs:

Michel Sadelain, MD, PhD – Memorial Sloan Kettering Cancer Center
Ingunn Stromnes, PhD – University of Minnesota

8:05 a.m. Targeting Neoantigens
8:25 a.m.

Dual Targeting CAR T cell
Crystal Mackall, MD – Stanford University

8:45 a.m. Early Stage Cellular Therapy Trials
Katyoun Rezvani, MD, PhD – University of Texas MD Anderson Cancer Center
9:05 a.m. Gene Editing
Carl H. June, MD – University of Pennsylvania
9:25 a.m. “Off the Shelf”
Jeffrey S. Miller, MD – University of Minnesota
9:45 a.m. Abstract Presentation
10 a.m. Abstract Presentation
Session 401: Update Session
Time: 10:30 10:45 a.m.
Session 402: Hot Topic Symposium
Time: 10:45 a.m. – 12:15 p.m.


​​​​​​​​​​​​​​​​​​​​